195 related articles for article (PubMed ID: 12733726)
1. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
[TBL] [Abstract][Full Text] [Related]
2. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
4. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
5. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
6. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
7. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
8. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate use in the treatment of Paget's disease of the bone: analysis of claims in a large database.
Dolgitser M; Stern L; Katz LM; Doyle JJ; Omar M; Seton M; Kahler KH
Manag Care Interface; 2007 Feb; 20(2):33-40. PubMed ID: 17405580
[TBL] [Abstract][Full Text] [Related]
10. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.
Eekhoff ME; Zwinderman AH; Haverkort DM; Cremers SC; Hamdy NA; Papapoulos SE
Bone; 2003 Nov; 33(5):831-8. PubMed ID: 14623059
[TBL] [Abstract][Full Text] [Related]
11. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease.
Rutland M; Wattie D; Que L; Hassan IM; Cundy T
Calcif Tissue Int; 2002 Feb; 70(2):99-102. PubMed ID: 11870415
[TBL] [Abstract][Full Text] [Related]
14. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
[TBL] [Abstract][Full Text] [Related]
16. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
Chapurlat R; Meunier PJ
Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
[TBL] [Abstract][Full Text] [Related]
17. Management of Paget's disease of bone.
Langston AL; Ralston SH
Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
[TBL] [Abstract][Full Text] [Related]
18. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
19. Paget's disease of bone.
Siris ES
J Bone Miner Res; 1998 Jul; 13(7):1061-5. PubMed ID: 9661069
[TBL] [Abstract][Full Text] [Related]
20. Paget's disease of bone: presentation, extent and response to bisphosphonates.
Wang LM; Au-Yeong ML; McKenna MJ
Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]